nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Digestion impaired—Temozolomide—melanoma	0.012	0.0192	CcSEcCtD
Lisdexamfetamine—Aggression—Bleomycin—melanoma	0.0109	0.0174	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.0103	0.0165	CcSEcCtD
Lisdexamfetamine—Weight decreased—Vemurafenib—melanoma	0.00894	0.0143	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.00874	0.014	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Vemurafenib—melanoma	0.00748	0.0119	CcSEcCtD
Lisdexamfetamine—Eye disorder—Vemurafenib—melanoma	0.0074	0.0118	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Vemurafenib—melanoma	0.00734	0.0117	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Vemurafenib—melanoma	0.00713	0.0114	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Bleomycin—melanoma	0.00707	0.0113	CcSEcCtD
Lisdexamfetamine—Malnutrition—Vemurafenib—melanoma	0.00689	0.011	CcSEcCtD
Lisdexamfetamine—Diplopia—Carmustine—melanoma	0.00605	0.00966	CcSEcCtD
Lisdexamfetamine—Diplopia—Temozolomide—melanoma	0.00585	0.00934	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00582	0.0093	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.00582	0.0093	CcSEcCtD
Lisdexamfetamine—Affect lability—Temozolomide—melanoma	0.00575	0.00919	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Vemurafenib—melanoma	0.00562	0.00898	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Vemurafenib—melanoma	0.00551	0.00881	CcSEcCtD
Lisdexamfetamine—Skin disorder—Vemurafenib—melanoma	0.00546	0.00872	CcSEcCtD
Lisdexamfetamine—Weight decreased—Bleomycin—melanoma	0.00542	0.00865	CcSEcCtD
Lisdexamfetamine—Blood pressure increased—Docetaxel—melanoma	0.00536	0.00855	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Bleomycin—melanoma	0.00526	0.00841	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Temozolomide—melanoma	0.00526	0.00841	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Bleomycin—melanoma	0.00524	0.00836	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00494	0.00789	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Vemurafenib—melanoma	0.00489	0.00781	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00485	0.00775	CcSEcCtD
Lisdexamfetamine—Fatigue—Vemurafenib—melanoma	0.00485	0.00774	CcSEcCtD
Lisdexamfetamine—Constipation—Vemurafenib—melanoma	0.00481	0.00768	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Temozolomide—melanoma	0.00465	0.00743	CcSEcCtD
Lisdexamfetamine—Depression—Carmustine—melanoma	0.00465	0.00742	CcSEcCtD
Lisdexamfetamine—Weight increased—Temozolomide—melanoma	0.0046	0.00734	CcSEcCtD
Lisdexamfetamine—Weight decreased—Temozolomide—melanoma	0.00457	0.0073	CcSEcCtD
Lisdexamfetamine—Depression—Temozolomide—melanoma	0.00449	0.00717	CcSEcCtD
Lisdexamfetamine—Hepatitis—Dactinomycin—melanoma	0.00447	0.00714	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00447	0.00713	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Vemurafenib—melanoma	0.00444	0.0071	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Temozolomide—melanoma	0.00426	0.0068	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Dactinomycin—melanoma	0.00423	0.00675	CcSEcCtD
Lisdexamfetamine—Hallucination—Carmustine—melanoma	0.00416	0.00665	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Vemurafenib—melanoma	0.00414	0.00662	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Docetaxel—melanoma	0.0041	0.00655	CcSEcCtD
Lisdexamfetamine—Hepatitis—Temozolomide—melanoma	0.00404	0.00646	CcSEcCtD
Lisdexamfetamine—Asthenia—Vemurafenib—melanoma	0.00403	0.00644	CcSEcCtD
Lisdexamfetamine—Visual impairment—Carmustine—melanoma	0.00403	0.00644	CcSEcCtD
Lisdexamfetamine—Hallucination—Temozolomide—melanoma	0.00402	0.00643	CcSEcCtD
Lisdexamfetamine—Eye disorder—Carmustine—melanoma	0.00391	0.00625	CcSEcCtD
Lisdexamfetamine—Visual impairment—Temozolomide—melanoma	0.0039	0.00622	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vemurafenib—melanoma	0.00385	0.00614	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Temozolomide—melanoma	0.00382	0.00611	CcSEcCtD
Lisdexamfetamine—Eye disorder—Temozolomide—melanoma	0.00378	0.00604	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Temozolomide—melanoma	0.00375	0.00599	CcSEcCtD
Lisdexamfetamine—Dizziness—Vemurafenib—melanoma	0.00372	0.00594	CcSEcCtD
Lisdexamfetamine—Mental disorder—Carmustine—melanoma	0.00367	0.00586	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Temozolomide—melanoma	0.00365	0.00583	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Temozolomide—melanoma	0.00364	0.00582	CcSEcCtD
Lisdexamfetamine—Malnutrition—Carmustine—melanoma	0.00364	0.00582	CcSEcCtD
Lisdexamfetamine—Vomiting—Vemurafenib—melanoma	0.00357	0.00571	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Docetaxel—melanoma	0.00355	0.00567	CcSEcCtD
Lisdexamfetamine—Rash—Vemurafenib—melanoma	0.00354	0.00566	CcSEcCtD
Lisdexamfetamine—Mental disorder—Temozolomide—melanoma	0.00354	0.00566	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vemurafenib—melanoma	0.00354	0.00566	CcSEcCtD
Lisdexamfetamine—Headache—Vemurafenib—melanoma	0.00352	0.00562	CcSEcCtD
Lisdexamfetamine—Malnutrition—Temozolomide—melanoma	0.00352	0.00562	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Docetaxel—melanoma	0.0035	0.00559	CcSEcCtD
Lisdexamfetamine—Vision blurred—Carmustine—melanoma	0.00343	0.00548	CcSEcCtD
Lisdexamfetamine—Tremor—Carmustine—melanoma	0.00341	0.00545	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Bleomycin—melanoma	0.00341	0.00544	CcSEcCtD
Lisdexamfetamine—Lacosamide—SCN10A—melanoma	0.00337	0.635	CrCbGaD
Lisdexamfetamine—Agitation—Carmustine—melanoma	0.00335	0.00535	CcSEcCtD
Lisdexamfetamine—Nausea—Vemurafenib—melanoma	0.00334	0.00533	CcSEcCtD
Lisdexamfetamine—Vision blurred—Temozolomide—melanoma	0.00332	0.0053	CcSEcCtD
Lisdexamfetamine—Tremor—Temozolomide—melanoma	0.0033	0.00527	CcSEcCtD
Lisdexamfetamine—Anorexia—Bleomycin—melanoma	0.00325	0.00519	CcSEcCtD
Lisdexamfetamine—Agitation—Temozolomide—melanoma	0.00324	0.00517	CcSEcCtD
Lisdexamfetamine—Angioedema—Temozolomide—melanoma	0.00322	0.00514	CcSEcCtD
Lisdexamfetamine—Convulsion—Carmustine—melanoma	0.00316	0.00504	CcSEcCtD
Lisdexamfetamine—Hypertension—Carmustine—melanoma	0.00315	0.00502	CcSEcCtD
Lisdexamfetamine—Palpitations—Temozolomide—melanoma	0.00311	0.00497	CcSEcCtD
Lisdexamfetamine—Anxiety—Carmustine—melanoma	0.00309	0.00494	CcSEcCtD
Lisdexamfetamine—Weight increased—Docetaxel—melanoma	0.00306	0.00488	CcSEcCtD
Lisdexamfetamine—Convulsion—Temozolomide—melanoma	0.00305	0.00487	CcSEcCtD
Lisdexamfetamine—Weight decreased—Docetaxel—melanoma	0.00304	0.00485	CcSEcCtD
Lisdexamfetamine—Hypertension—Temozolomide—melanoma	0.00304	0.00485	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Bleomycin—melanoma	0.00304	0.00485	CcSEcCtD
Lisdexamfetamine—Anorexia—Dactinomycin—melanoma	0.00303	0.00484	CcSEcCtD
Lisdexamfetamine—Anxiety—Temozolomide—melanoma	0.00299	0.00477	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00298	0.00475	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00297	0.00474	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Bleomycin—melanoma	0.00296	0.00473	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Docetaxel—melanoma	0.00295	0.00472	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Docetaxel—melanoma	0.00294	0.00469	CcSEcCtD
Lisdexamfetamine—Dry mouth—Temozolomide—melanoma	0.00293	0.00468	CcSEcCtD
Lisdexamfetamine—Tachycardia—Carmustine—melanoma	0.0029	0.00463	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Temozolomide—melanoma	0.00287	0.00459	CcSEcCtD
Lisdexamfetamine—Anorexia—Carmustine—melanoma	0.00283	0.00453	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Docetaxel—melanoma	0.00283	0.00453	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Temozolomide—melanoma	0.00282	0.0045	CcSEcCtD
Lisdexamfetamine—Skin disorder—Temozolomide—melanoma	0.00279	0.00446	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Temozolomide—melanoma	0.00278	0.00444	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Dactinomycin—melanoma	0.00276	0.00441	CcSEcCtD
Lisdexamfetamine—Fatigue—Dactinomycin—melanoma	0.00274	0.00437	CcSEcCtD
Lisdexamfetamine—Anorexia—Temozolomide—melanoma	0.00274	0.00437	CcSEcCtD
Lisdexamfetamine—Urticaria—Bleomycin—melanoma	0.00271	0.00432	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Bleomycin—melanoma	0.00269	0.0043	CcSEcCtD
Lisdexamfetamine—Hepatitis—Docetaxel—melanoma	0.00269	0.0043	CcSEcCtD
Lisdexamfetamine—Insomnia—Carmustine—melanoma	0.00269	0.00429	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Carmustine—melanoma	0.00265	0.00423	CcSEcCtD
Lisdexamfetamine—Somnolence—Carmustine—melanoma	0.00264	0.00422	CcSEcCtD
Lisdexamfetamine—Insomnia—Temozolomide—melanoma	0.0026	0.00415	CcSEcCtD
Lisdexamfetamine—Visual impairment—Docetaxel—melanoma	0.00259	0.00414	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Carmustine—melanoma	0.00258	0.00413	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Carmustine—melanoma	0.00257	0.0041	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Temozolomide—melanoma	0.00256	0.00409	CcSEcCtD
Lisdexamfetamine—Somnolence—Temozolomide—melanoma	0.00255	0.00408	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Docetaxel—melanoma	0.00254	0.00406	CcSEcCtD
Lisdexamfetamine—Constipation—Carmustine—melanoma	0.00254	0.00406	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Temozolomide—melanoma	0.00253	0.00404	CcSEcCtD
Lisdexamfetamine—Eye disorder—Docetaxel—melanoma	0.00251	0.00401	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dactinomycin—melanoma	0.00251	0.00401	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Bleomycin—melanoma	0.00251	0.00401	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Temozolomide—melanoma	0.0025	0.00399	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Docetaxel—melanoma	0.0025	0.00399	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Temozolomide—melanoma	0.00248	0.00396	CcSEcCtD
Lisdexamfetamine—Fatigue—Temozolomide—melanoma	0.00248	0.00396	CcSEcCtD
Lisdexamfetamine—Constipation—Temozolomide—melanoma	0.00246	0.00392	CcSEcCtD
Lisdexamfetamine—Asthenia—Bleomycin—melanoma	0.00244	0.0039	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Docetaxel—melanoma	0.00243	0.00388	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Docetaxel—melanoma	0.00242	0.00387	CcSEcCtD
Lisdexamfetamine—Mental disorder—Docetaxel—melanoma	0.00236	0.00376	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Carmustine—melanoma	0.00235	0.00375	CcSEcCtD
Lisdexamfetamine—Malnutrition—Docetaxel—melanoma	0.00234	0.00374	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Dactinomycin—melanoma	0.00234	0.00374	CcSEcCtD
Lisdexamfetamine—Urticaria—Temozolomide—melanoma	0.00228	0.00365	CcSEcCtD
Lisdexamfetamine—Asthenia—Dactinomycin—melanoma	0.00228	0.00364	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Temozolomide—melanoma	0.00227	0.00363	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Carmustine—melanoma	0.00219	0.0035	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Dactinomycin—melanoma	0.00217	0.00347	CcSEcCtD
Lisdexamfetamine—Vomiting—Bleomycin—melanoma	0.00217	0.00346	CcSEcCtD
Lisdexamfetamine—Rash—Bleomycin—melanoma	0.00215	0.00343	CcSEcCtD
Lisdexamfetamine—Dermatitis—Bleomycin—melanoma	0.00215	0.00343	CcSEcCtD
Lisdexamfetamine—Asthenia—Carmustine—melanoma	0.00213	0.00341	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Temozolomide—melanoma	0.00212	0.00338	CcSEcCtD
Lisdexamfetamine—Palpitations—Docetaxel—melanoma	0.00207	0.0033	CcSEcCtD
Lisdexamfetamine—Asthenia—Temozolomide—melanoma	0.00206	0.00329	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Carmustine—melanoma	0.00203	0.00325	CcSEcCtD
Lisdexamfetamine—Convulsion—Docetaxel—melanoma	0.00203	0.00324	CcSEcCtD
Lisdexamfetamine—Nausea—Bleomycin—melanoma	0.00202	0.00323	CcSEcCtD
Lisdexamfetamine—Hypertension—Docetaxel—melanoma	0.00202	0.00323	CcSEcCtD
Lisdexamfetamine—Vomiting—Dactinomycin—melanoma	0.00202	0.00323	CcSEcCtD
Lisdexamfetamine—Rash—Dactinomycin—melanoma	0.002	0.0032	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00198	0.00316	CcSEcCtD
Lisdexamfetamine—Dizziness—Carmustine—melanoma	0.00197	0.00314	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Temozolomide—melanoma	0.00197	0.00314	CcSEcCtD
Lisdexamfetamine—Dry mouth—Docetaxel—melanoma	0.00195	0.00311	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Docetaxel—melanoma	0.00191	0.00305	CcSEcCtD
Lisdexamfetamine—Dizziness—Temozolomide—melanoma	0.0019	0.00303	CcSEcCtD
Lisdexamfetamine—Vomiting—Carmustine—melanoma	0.00189	0.00302	CcSEcCtD
Lisdexamfetamine—Nausea—Dactinomycin—melanoma	0.00189	0.00301	CcSEcCtD
Lisdexamfetamine—Rash—Carmustine—melanoma	0.00187	0.00299	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Docetaxel—melanoma	0.00187	0.00299	CcSEcCtD
Lisdexamfetamine—Dermatitis—Carmustine—melanoma	0.00187	0.00299	CcSEcCtD
Lisdexamfetamine—Tachycardia—Docetaxel—melanoma	0.00186	0.00298	CcSEcCtD
Lisdexamfetamine—Headache—Carmustine—melanoma	0.00186	0.00297	CcSEcCtD
Lisdexamfetamine—Skin disorder—Docetaxel—melanoma	0.00186	0.00296	CcSEcCtD
Lisdexamfetamine—Vomiting—Temozolomide—melanoma	0.00183	0.00292	CcSEcCtD
Lisdexamfetamine—Anorexia—Docetaxel—melanoma	0.00182	0.00291	CcSEcCtD
Lisdexamfetamine—Rash—Temozolomide—melanoma	0.00181	0.00289	CcSEcCtD
Lisdexamfetamine—Dermatitis—Temozolomide—melanoma	0.00181	0.00289	CcSEcCtD
Lisdexamfetamine—Headache—Temozolomide—melanoma	0.0018	0.00287	CcSEcCtD
Lisdexamfetamine—Nausea—Carmustine—melanoma	0.00177	0.00282	CcSEcCtD
Lisdexamfetamine—Insomnia—Docetaxel—melanoma	0.00173	0.00276	CcSEcCtD
Lisdexamfetamine—Nausea—Temozolomide—melanoma	0.00171	0.00273	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Docetaxel—melanoma	0.0017	0.00272	CcSEcCtD
Lisdexamfetamine—Somnolence—Docetaxel—melanoma	0.0017	0.00271	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Docetaxel—melanoma	0.00168	0.00269	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Docetaxel—melanoma	0.00166	0.00265	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Docetaxel—melanoma	0.00165	0.00263	CcSEcCtD
Lisdexamfetamine—Fatigue—Docetaxel—melanoma	0.00165	0.00263	CcSEcCtD
Lisdexamfetamine—Constipation—Docetaxel—melanoma	0.00163	0.00261	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Docetaxel—melanoma	0.00151	0.00241	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Docetaxel—melanoma	0.00141	0.00225	CcSEcCtD
Lisdexamfetamine—Asthenia—Docetaxel—melanoma	0.00137	0.00219	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Docetaxel—melanoma	0.00131	0.00209	CcSEcCtD
Lisdexamfetamine—Dizziness—Docetaxel—melanoma	0.00126	0.00202	CcSEcCtD
Lisdexamfetamine—Lisinopril—ABCB1—melanoma	0.00124	0.234	CrCbGaD
Lisdexamfetamine—Vomiting—Docetaxel—melanoma	0.00121	0.00194	CcSEcCtD
Lisdexamfetamine—Rash—Docetaxel—melanoma	0.0012	0.00192	CcSEcCtD
Lisdexamfetamine—Dermatitis—Docetaxel—melanoma	0.0012	0.00192	CcSEcCtD
Lisdexamfetamine—Headache—Docetaxel—melanoma	0.0012	0.00191	CcSEcCtD
Lisdexamfetamine—Nausea—Docetaxel—melanoma	0.00113	0.00181	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—GNAQ—melanoma	0.000774	0.0021	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CXCL8—melanoma	0.000765	0.00208	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—melanoma	0.000756	0.00205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GRM3—melanoma	0.000752	0.00204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CB—melanoma	0.00075	0.00203	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—melanoma	0.000745	0.00202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—melanoma	0.000732	0.00199	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—KISS1—melanoma	0.000713	0.00193	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR2—melanoma	0.000709	0.00192	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—melanoma	0.000707	0.00192	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—F2R—melanoma	0.000704	0.00191	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TAS2R60—melanoma	0.000701	0.0019	CbGpPWpGaD
Lisdexamfetamine—Selegiline—ABCB1—melanoma	0.000697	0.131	CrCbGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—melanoma	0.000693	0.00188	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—melanoma	0.000692	0.00188	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCR1—melanoma	0.00069	0.00187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—NFKB1—melanoma	0.000685	0.00186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—EDNRB—melanoma	0.000682	0.00185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—MC1R—melanoma	0.00068	0.00184	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—PRKCA—melanoma	0.000675	0.00183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR7—melanoma	0.000652	0.00177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GRM1—melanoma	0.000652	0.00177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CDKN1A—melanoma	0.000649	0.00176	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TAS2R60—melanoma	0.000637	0.00173	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MDM2—melanoma	0.000633	0.00172	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—PRKCA—melanoma	0.000612	0.00166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR4—melanoma	0.000605	0.00164	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.000603	0.00164	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—melanoma	0.000603	0.00164	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—EDN1—melanoma	0.0006	0.00163	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.000584	0.00158	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—BRAF—melanoma	0.000579	0.00157	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—melanoma	0.000566	0.00154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—melanoma	0.000559	0.00152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCR2—melanoma	0.00054	0.00147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—melanoma	0.000537	0.00146	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PLCB4—melanoma	0.000531	0.00144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL1—melanoma	0.000531	0.00144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—WNT5A—melanoma	0.000523	0.00142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR4—melanoma	0.000519	0.00141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCA—melanoma	0.000503	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K2—melanoma	0.000492	0.00133	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MDM2—melanoma	0.000485	0.00132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PLCB4—melanoma	0.000483	0.00131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL1—melanoma	0.000483	0.00131	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—PRKCA—melanoma	0.000469	0.00127	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—melanoma	0.00046	0.00125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—F2R—melanoma	0.000459	0.00125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—melanoma	0.000457	0.00124	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—F2RL1—melanoma	0.000452	0.00123	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—melanoma	0.000451	0.00122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HRAS—melanoma	0.000449	0.00122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—EDNRB—melanoma	0.000445	0.00121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYO7A—melanoma	0.000442	0.0012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRAP1—melanoma	0.000442	0.0012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—melanoma	0.000442	0.0012	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MAPK1—melanoma	0.000433	0.00117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—melanoma	0.000428	0.00116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM3—melanoma	0.000425	0.00115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—F2RL1—melanoma	0.00041	0.00111	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—melanoma	0.000406	0.0011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—KISS1—melanoma	0.000403	0.00109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.000398	0.00108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—melanoma	0.000397	0.00108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCR4—melanoma	0.000395	0.00107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCR1—melanoma	0.00039	0.00106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM3—melanoma	0.000386	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—MC1R—melanoma	0.000384	0.00104	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—melanoma	0.000381	0.00103	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MDM2—melanoma	0.000378	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TAS2R60—melanoma	0.000376	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—melanoma	0.000373	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR7—melanoma	0.000368	0.001	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM1—melanoma	0.000368	0.001	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KISS1—melanoma	0.000366	0.000992	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—melanoma	0.000359	0.000975	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCR1—melanoma	0.000354	0.000961	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MC1R—melanoma	0.000349	0.000947	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—melanoma	0.000349	0.000946	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—melanoma	0.000348	0.000943	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BRAF—melanoma	0.000345	0.000937	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—melanoma	0.000337	0.000915	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RHOB—melanoma	0.000335	0.000909	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR7—melanoma	0.000335	0.000908	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM1—melanoma	0.000335	0.000908	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MAPK1—melanoma	0.000332	0.0009	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—melanoma	0.000309	0.000839	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCR2—melanoma	0.000305	0.000828	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RHOB—melanoma	0.000304	0.000826	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—EDN1—melanoma	0.000303	0.000822	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RAC2—melanoma	0.0003	0.000815	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MDM2—melanoma	0.000289	0.000785	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—melanoma	0.000288	0.00078	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL1—melanoma	0.000285	0.000774	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLCB4—melanoma	0.000285	0.000774	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCR2—melanoma	0.000277	0.000752	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—melanoma	0.000274	0.000743	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RAC2—melanoma	0.000273	0.00074	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—WNT5A—melanoma	0.000268	0.000728	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TRRAP—melanoma	0.000268	0.000727	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CUL3—melanoma	0.000268	0.000727	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—melanoma	0.000266	0.000723	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKR1B10—melanoma	0.000261	0.000708	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—F2R—melanoma	0.00026	0.000704	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—melanoma	0.000258	0.0007	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDNRB—melanoma	0.000251	0.000682	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—F2RL1—melanoma	0.000242	0.000658	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GAB2—melanoma	0.000237	0.000644	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNA11—melanoma	0.000237	0.000644	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—F2R—melanoma	0.000236	0.00064	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—melanoma	0.000233	0.000632	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDNRB—melanoma	0.000228	0.000619	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM3—melanoma	0.000228	0.000618	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCR4—melanoma	0.000223	0.000606	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—melanoma	0.000223	0.000605	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNAQ—melanoma	0.000221	0.000599	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KISS1—melanoma	0.000216	0.000586	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GAB2—melanoma	0.000216	0.000585	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNA11—melanoma	0.000216	0.000585	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000215	0.000583	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—melanoma	0.000212	0.000576	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—melanoma	0.000212	0.000576	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SKI—melanoma	0.000209	0.000568	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCR1—melanoma	0.000209	0.000568	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—melanoma	0.000207	0.000562	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MC1R—melanoma	0.000206	0.000559	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—melanoma	0.000206	0.000559	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT3—melanoma	0.000204	0.000553	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCR4—melanoma	0.000203	0.00055	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNAQ—melanoma	0.0002	0.000544	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—melanoma	0.0002	0.000544	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MAPK1—melanoma	0.000198	0.000537	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM1—melanoma	0.000198	0.000536	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR7—melanoma	0.000198	0.000536	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—melanoma	0.000193	0.000525	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SUFU—melanoma	0.000193	0.000523	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT3—melanoma	0.000185	0.000502	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—melanoma	0.000184	0.0005	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RHOB—melanoma	0.00018	0.000488	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BCL2L11—melanoma	0.00018	0.000488	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC6—melanoma	0.000173	0.000469	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—melanoma	0.000171	0.000465	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDN1—melanoma	0.000171	0.000464	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	0.00017	0.000462	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CSF2—melanoma	0.000167	0.000454	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCR2—melanoma	0.000164	0.000444	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—melanoma	0.000164	0.000444	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	0.000163	0.000442	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAC2—melanoma	0.000161	0.000437	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCA—melanoma	0.00016	0.000435	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—melanoma	0.000159	0.000431	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WNT5A—melanoma	0.000159	0.00043	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFC—melanoma	0.000159	0.00043	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDN1—melanoma	0.000155	0.000422	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CSF2—melanoma	0.000152	0.000412	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RAC1—melanoma	0.000149	0.000403	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCA—melanoma	0.000146	0.000395	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAP2K2—melanoma	0.000142	0.000386	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—F2R—melanoma	0.000139	0.000378	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RAC1—melanoma	0.000135	0.000366	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDNRB—melanoma	0.000135	0.000366	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTK2B—melanoma	0.000131	0.000355	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNA11—melanoma	0.000127	0.000346	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GAB2—melanoma	0.000127	0.000346	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FLT1—melanoma	0.000127	0.000344	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—melanoma	0.000126	0.000341	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC2—melanoma	0.00012	0.000325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FOXO4—melanoma	0.00012	0.000325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCR4—melanoma	0.00012	0.000325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNAQ—melanoma	0.000118	0.000321	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—melanoma	0.000114	0.000309	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SYK—melanoma	0.000111	0.000302	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—melanoma	0.00011	0.0003	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT3—melanoma	0.000109	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ITGAV—melanoma	0.000109	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGFR—melanoma	0.000109	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SOCS1—melanoma	0.000101	0.000274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAP2K1—melanoma	0.000101	0.000274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—S100B—melanoma	0.000101	0.000274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—melanoma	0.0001	0.000272	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB4—melanoma	9.65e-05	0.000262	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—melanoma	9.62e-05	0.000261	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN2B—melanoma	9.57e-05	0.00026	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CD86—melanoma	9.25e-05	0.000251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—melanoma	9.25e-05	0.000251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDN1—melanoma	9.18e-05	0.000249	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CSF2—melanoma	8.97e-05	0.000243	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF1—melanoma	8.97e-05	0.000243	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—melanoma	8.84e-05	0.00024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—E2F1—melanoma	8.78e-05	0.000238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—melanoma	8.74e-05	0.000237	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFRA—melanoma	8.69e-05	0.000236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ITGB3—melanoma	8.6e-05	0.000233	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCA—melanoma	8.6e-05	0.000233	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SPP1—melanoma	8.44e-05	0.000229	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAP2K2—melanoma	8.41e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—melanoma	8.4e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—melanoma	8.03e-05	0.000218	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—melanoma	8e-05	0.000217	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAC1—melanoma	7.97e-05	0.000216	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIF1A—melanoma	7.65e-05	0.000208	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—melanoma	7.31e-05	0.000198	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FN1—melanoma	7.04e-05	0.000191	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH1—melanoma	6.89e-05	0.000187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CD80—melanoma	6.75e-05	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KIT—melanoma	6.74e-05	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—melanoma	6.74e-05	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—melanoma	6.74e-05	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NRAS—melanoma	6.74e-05	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGF—melanoma	6.66e-05	0.000181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK3—melanoma	6.45e-05	0.000175	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BRAF—melanoma	6.33e-05	0.000172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—melanoma	6.17e-05	0.000167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK1—melanoma	6.14e-05	0.000167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—melanoma	6.14e-05	0.000167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAP2K1—melanoma	5.96e-05	0.000162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—melanoma	5.92e-05	0.000161	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—melanoma	5.87e-05	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—melanoma	5.8e-05	0.000157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF2—melanoma	5.67e-05	0.000154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	5.33e-05	0.000145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MDM2—melanoma	5.31e-05	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—melanoma	5.23e-05	0.000142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—melanoma	5.16e-05	0.00014	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—melanoma	4.96e-05	0.000135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—melanoma	4.93e-05	0.000134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—melanoma	4.84e-05	0.000131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—melanoma	4.79e-05	0.00013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—melanoma	4.75e-05	0.000129	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—melanoma	4.74e-05	0.000129	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—melanoma	4.72e-05	0.000128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—melanoma	4.62e-05	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNB1—melanoma	4.58e-05	0.000124	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—melanoma	4.49e-05	0.000122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1A—melanoma	4.47e-05	0.000121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—melanoma	4.46e-05	0.000121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NFKB1—melanoma	4.44e-05	0.00012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—melanoma	4.35e-05	0.000118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—melanoma	4.03e-05	0.000109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—melanoma	3.99e-05	0.000108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRAS—melanoma	3.98e-05	0.000108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK3—melanoma	3.81e-05	0.000103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—melanoma	3.71e-05	0.000101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK1—melanoma	3.63e-05	9.84e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—melanoma	3.63e-05	9.84e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—melanoma	3.43e-05	9.29e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	3.15e-05	8.54e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—melanoma	3.04e-05	8.26e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—melanoma	2.91e-05	7.9e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—melanoma	2.79e-05	7.56e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—melanoma	2.57e-05	6.98e-05	CbGpPWpGaD
